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1.. INTRODUCTION {#hec4029-sec-0001}
================

Health technology assessment (HTA) could help to identify and prioritize cost‐effective interventions to support universal health coverage (UHC; World Health Organization, [2014a](#hec4029-bib-0043){ref-type="ref"}; World Health Organization, [2014b](#hec4029-bib-0044){ref-type="ref"}). However, conducting economic evaluations, such as cost‐effectiveness analysis (CEA), can be challenging because these analyses require additional training, appropriate data inputs, and contextual considerations (Drummond, Sculpher, Claxton, Stoddart, & Torrance, [2015](#hec4029-bib-0013){ref-type="ref"}; Sanders et al., [2016](#hec4029-bib-0038){ref-type="ref"}). As such, HTA agencies have not yet been formalized in most low‐ and middle‐income countries (LMIC), particularly in Africa, where nearly half of countries in the sub‐Saharan region are classified as low‐income, making prioritization of constrained resources critical (Bank, [2019](#hec4029-bib-0005){ref-type="ref"}; Chalkidou et al., [2016](#hec4029-bib-0009){ref-type="ref"}; Li, Hernandez‐Villafuerte, Towse, Vlad, & Chalkidou, [2016](#hec4029-bib-0029){ref-type="ref"}). Also, there are uncertainties around whether these countries have the technical capacity and organizational support to generate economic evidence suitable to their contexts and settings (Babigumira Jenny, Bartlein, Stergachis, & Garrison, [2016](#hec4029-bib-0004){ref-type="ref"}; Chuang, Chuang, Ho, & Ho, [2011](#hec4029-bib-0010){ref-type="ref"}; Doherty, Wilkinson, Edoka, & Hofman, [2017](#hec4029-bib-0012){ref-type="ref"}; Hofman, Kanyengo, Rapp, & Kotzin, [2009](#hec4029-bib-0024){ref-type="ref"}; Pitt, Goodman, & Hanson, [2016](#hec4029-bib-0036){ref-type="ref"}; Tantivess, Chalkidou, Tritasavit, & Teerawattananon, [2017](#hec4029-bib-0040){ref-type="ref"}; Wagstaff & Culyer, [2011](#hec4029-bib-0041){ref-type="ref"}).

With the substantial growth and the increased accessibility of such information, (Center For The Evaluation Of Value And Risk In Health (CEVR), Tufts Medical Center ([2019a](#hec4029-bib-0007){ref-type="ref"},[b](#hec4029-bib-0008){ref-type="ref"}) a comprehensive review of economic evaluations conducted for Africa would shed light on the growth, characteristics, and quality of cost‐effectiveness studies as well as identify gaps in the field. Previous bibliometric analyses of economic evaluations in Africa are limited in scope and outdated, highlighting the need for comprehensive and updated analyses (Chuang et al., [2011](#hec4029-bib-0010){ref-type="ref"}; Hernandez‐Villafuerte, Li, & Hofman, [2016](#hec4029-bib-0022){ref-type="ref"}; Hofman et al., [2009](#hec4029-bib-0024){ref-type="ref"}; Odame, [2013](#hec4029-bib-0035){ref-type="ref"}). Additionally, given the extensive benefits of the increasing level of international collaborations to generate and use economic evidence in global health policy (Atkinson, Batchelor, & Parsons, [1998](#hec4029-bib-0003){ref-type="ref"}; Ettarh, [2015](#hec4029-bib-0018){ref-type="ref"}; Fershtman & Gandal, [2011](#hec4029-bib-0019){ref-type="ref"}; Hoekman, Frenken, & van Oort, [2008](#hec4029-bib-0023){ref-type="ref"}; Imperial College London & Center for Global Development, [2019](#hec4029-bib-0026){ref-type="ref"}; Lachat et al., [2015](#hec4029-bib-0028){ref-type="ref"}), a formal assessment of institutional capacity and relationship patterns among authors can identify potential opportunities for capacity building and future collaboration.

2.. METHODS {#hec4029-sec-0002}
===========

2.1.. Literature search {#hec4029-sec-0003}
-----------------------

To identify CEAs conducted for African countries ([Appendix S1](#hec4029-supitem-0001){ref-type="supplementary-material"}), we analyzed the Tufts Medical Center\'s CEA Registry (a database of cost‐per‐quality‐adjusted‐life‐year \[QALY\] studies) and Global Health CEA Registry (a database of cost‐per‐disability‐adjusted‐life‐year \[DALY\] studies; Center For The Evaluation Of Value And Risk In Health (CEVR), Tufts Medical Center, [2019a](#hec4029-bib-0007){ref-type="ref"},[b](#hec4029-bib-0008){ref-type="ref"}). Both registries contain information from English‐language, original CEAs indexed in PubMed, and report at least one cost‐per‐QALY gained or cost‐per‐DALY averted ratio. Previous work documents additional methodology in detail (Butt, Liu, Kim, & Neumann, [2019](#hec4029-bib-0006){ref-type="ref"}; Neumann et al., [2016](#hec4029-bib-0033){ref-type="ref"}). To supplement the registries, we also searched four other databases (i.e., the National Health Service Economic Evaluation Database, Nixon et al., [2000](#hec4029-bib-0034){ref-type="ref"}; Embase, Elsevier, [2018](#hec4029-bib-0014){ref-type="ref"}; EconLit, American Economic Association, [2019](#hec4029-bib-0002){ref-type="ref"}; and Web of Science, Clarivate Analytics, [2019](#hec4029-bib-0011){ref-type="ref"}) with a defined set of search terms available in [Appendix S2](#hec4029-supitem-0001){ref-type="supplementary-material"}.

2.2.. Screening and data extraction {#hec4029-sec-0004}
-----------------------------------

Two researchers (A. D. P. and J. G. E.) independently screened the title and abstract of each article identified from non‐Tufts registry sources and determined whether the study met our inclusion criteria. [Appendix S3](#hec4029-supitem-0001){ref-type="supplementary-material"} provides the full inclusion criteria and a PRISMA diagram detailing the screening process and results. We then conducted a full‐text review of the final sample using a standardized data collection form to extract variables relating to the study and author characteristics. [Appendix S4](#hec4029-supitem-0001){ref-type="supplementary-material"} provides a full list of extracted variables and descriptions.

2.3.. Data analysis {#hec4029-sec-0005}
-------------------

We examined the association between the number of available studies and study characteristics, including outcome measure, disease area, and intervention type at three time periods (pre‐2010, 2010--2014, and 2015--2017). We also analyzed whether the reported cost‐effectiveness ratios varied across the intervention types.

To determine the top contributing individuals and institutions, we ranked authors and institutions by the number of total published studies and examined the proportion of first authors with an African affiliation. We compared study characteristics published by the top three (contributing to more than 10 studies) versus other African institutions to evaluate whether the increased capacity and experience is associated with improved study quality. As a sensitivity analysis, we examined a study\'s adherence to the iDSI methodological and reporting guidelines (Emerson et al., [2019](#hec4029-bib-0017){ref-type="ref"}; Wilkinson et al., [2016](#hec4029-bib-0042){ref-type="ref"}). We performed chi‐square test or independent samples *t‐* test to evaluate a statistically significant difference.

We generated author dyads for each study and counted the frequency of each dyad to identify the pairs of authors most frequently collaborating with one another. Similarly, we repeated this approach to create institution and country dyads and quantified the extent of cross‐national and within‐Africa collaboration. We provide a worked example for more thorough explanation of dyad generation in [Appendix S5](#hec4029-supitem-0001){ref-type="supplementary-material"}.

All analyses were conducted in Stata 15 (StataCorp, [2017](#hec4029-bib-0039){ref-type="ref"}) and RStudio (RStudio, [2018](#hec4029-bib-0037){ref-type="ref"}).

3.. RESULTS {#hec4029-sec-0006}
===========

3.1.. Study sample {#hec4029-sec-0007}
------------------

We initially identified 1,251 studies indexed across the six databases and then removed 802 studies, including duplicates (*n* = 421) and those not meeting the inclusion criteria (*n* = 381). We excluded an additional 91 studies, which did not meet the inclusion criteria after reviewing the full text, resulting in 358 studies in the final sample, with 94% (*n* = 339) coming from the CEA and Global Health CEA registries.

3.2.. Study characteristics of CEAs conducted for Africa {#hec4029-sec-0008}
--------------------------------------------------------

The number of African CEAs published per year continuously increased over time (Figure [1](#hec4029-fig-0001){ref-type="fig"}). Among the 358 included studies, most (*n* = 344, 96%) focused on countries in sub‐Saharan Africa, whereas relatively few (*n* = 56, 16%) focused on countries in North Africa (Table [1](#hec4029-tbl-0001){ref-type="table"}). The DALY was a more prevalent health outcome measure (*n* = 274, 77%) than the QALY (*n* = 88, 25%). Studies most frequently assessed pharmaceutical interventions (*n* = 152, 42%) or immunizations (*n* = 78, 22%). Communicable diseases remained the primary focus of studies, including those published in the most recent period between 2015 and 2017. Uganda (*n* = 103), South Africa (*n* = 101), and Kenya (*n* = 91) were the three most studied countries (Figure [2](#hec4029-fig-0002){ref-type="fig"}; [Appendix S7](#hec4029-supitem-0001){ref-type="supplementary-material"}: Table A). Among 2,121 intervention‐specificcost‐effectiveness ratios extracted from 358 studies, 8% (*n* = 162) were deemed cost‐saving, and most of these evaluated immunizations, pharmaceuticals, or screening strategies. A greater proportion of cost‐per‐QALY ratios were reported to be cost‐saving compared with cost‐per‐DALY ratios (*n* = 34, 14% vs. *n* = 128, 7%; [Appendix S7: Table B](#hec4029-supitem-0001){ref-type="supplementary-material"}).

![Growth of African cost‐effectiveness analyses over time.\
*Note*: This figure shows the growth of African CEAs over time. The first CEA in our sample was published in 1992, which is not shown in the Figure. Studies reporting both QALYs and DALYs as health outcome measures are categorized separately. \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HEC-29-945-g001){#hec4029-fig-0001}

###### 

Characteristics of economic evaluations in Africa

                                                                                             Pre‐2010[^b^](#hec4029-note-0002){ref-type="fn"}   2010--2014[^b^](#hec4029-note-0002){ref-type="fn"}   2015‐2017[^b^](#hec4029-note-0002){ref-type="fn"}   Overall[^b^](#hec4029-note-0002){ref-type="fn"}                     
  ------------------------------------------------------------------------------------------ -------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ------------------------------------------------- ----- ----- ----- ------
  All studies                                                                                87                                                 24%                                                  142                                                 40%                                               129   36%   358   100%
  Health outcome measure[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                             
  Cost/DALY                                                                                  68                                                 78%                                                  106                                                 75%                                               100   78%   274   77%
  Cost/QALY                                                                                  20                                                 23%                                                  37                                                  26%                                               31    24%   88    25%
  GBD super region[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                                   
  Sub‐Saharan Africa                                                                         86                                                 99%                                                  136                                                 96%                                               122   95%   344   96%
  North Africa                                                                               15                                                 17%                                                  23                                                  16%                                               18    14%   56    16%
  Prevention level[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                                   
  Primary                                                                                    46                                                 53%                                                  68                                                  48%                                               58    45%   172   48%
  Secondary                                                                                  20                                                 23%                                                  23                                                  16%                                               21    16%   64    18%
  Tertiary                                                                                   36                                                 41%                                                  62                                                  44%                                               59    46%   157   44%
  Country vs. regional ratios[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                        
  Country‐specific                                                                           70                                                 80%                                                  120                                                 85%                                               113   88%   303   85%
  Regional                                                                                   18                                                 21%                                                  28                                                  20%                                               16    12%   62    17%
  Study Perspective                                                                                                                                                                                                                                                                                                          
  Societal/limited societal                                                                  22                                                 25%                                                  27                                                  19%                                               27    21%   76    21%
  Health care payer/sector                                                                   64                                                 74%                                                  108                                                 76%                                               99    77%   271   76%
  Other/could not be determined                                                              1                                                  1%                                                   7                                                   5%                                                3     2%    11    3%
  Top GBD disease categories[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                         
  HIV/AIDS and tuberculosis                                                                  33                                                 38%                                                  51                                                  36%                                               41    32%   125   35%
  Diarrhea, lower respiratory infections, meningitis, and other common infectious diseases   10                                                 11%                                                  26                                                  18%                                               20    16%   56    16%
  Neglected tropical diseases and malaria                                                    15                                                 17%                                                  17                                                  12%                                               15    12%   47    13%
  Other communicable, maternal, neonatal, and nutritional disorders                          13                                                 15%                                                  10                                                  7%                                                10    8%    33    9%
  Cardiovascular and circulatory diseases                                                    3                                                  3%                                                   8                                                   6%                                                6     5%    17    5%
  Maternal disorders                                                                         2                                                  2%                                                   3                                                   2%                                                10    8%    15    4%
  Nutritional deficiencies                                                                   4                                                  5%                                                   5                                                   4%                                                3     2%    12    3%
  Other noncommunicable diseases                                                             2                                                  2%                                                   4                                                   3%                                                5     4%    11    3%
  Neoplasms                                                                                  3                                                  3%                                                   5                                                   4%                                                2     2%    10    3%
  Diabetes, urogenital, blood, and endocrine diseases                                        0                                                  0%                                                   3                                                   2%                                                6     5%    9     3%
  Other diseases                                                                             10                                                 11%                                                  22                                                  15%                                               18    14%   50    14%
  Top interventions[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                                  
  Pharmaceutical                                                                             43                                                 49%                                                  61                                                  43%                                               48    37%   152   42%
  Immunization                                                                               19                                                 22%                                                  31                                                  22%                                               28    22%   78    22%
  Care delivery                                                                              17                                                 20%                                                  19                                                  13%                                               26    20%   62    17%
  Health education or behavior                                                               13                                                 15%                                                  15                                                  11%                                               19    15%   47    13%
  Screening                                                                                  12                                                 14%                                                  19                                                  13%                                               15    12%   46    13%
  Maternal and neonatal                                                                      9                                                  10%                                                  13                                                  9%                                                11    9%    33    9%
  Diagnostic                                                                                 4                                                  5%                                                   12                                                  8%                                                10    8%    26    7%
  Surgical                                                                                   4                                                  5%                                                   14                                                  10%                                               8     6%    26    7%
  Other interventions                                                                        23                                                 26%                                                  31                                                  22%                                               28    22%   82    23%
  Study sponsor[^a^](#hec4029-note-0001){ref-type="fn"}                                                                                                                                                                                                                                                                      
  Government/academic                                                                        53                                                 61%                                                  70                                                  49%                                               54    42%   177   49%
  Foundation                                                                                 25                                                 29%                                                  43                                                  30%                                               41    32%   109   30%
  Pharma/device company                                                                      6                                                  7%                                                   8                                                   6%                                                10    8%    24    7%
  Could not be determined/none                                                               18                                                 21%                                                  38                                                  27%                                               27    21%   83    23%
  Other                                                                                      12                                                 14%                                                  20                                                  14%                                               18    14%   50    14%

Not mutually exclusive categories.

Proportions are based on the total number of studies during each time point.

![Number of cost‐effectiveness analyses by African countries.\
*Note*: Cost‐effectiveness analyses include cost‐per‐QALY and cost‐per‐DALY studies. (See [Appendix S6: Figures B and C](#hec4029-supitem-0001){ref-type="supplementary-material"} for the literature‐specific maps.) In this figure, green indicates a relatively low number of studies while red indicates a relatively high number of studies. For example, the top three countries include Uganda (*N* = 103), South Africa (*N* = 101), and Kenya (*N* = 91), whereas the lowest three are Libya (*N* = 6), Tunisia (*N* = 9), and South Sudan (*N* = 10) \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HEC-29-945-g002){#hec4029-fig-0002}

3.3.. Institutional capacity and collaboration patterns {#hec4029-sec-0009}
-------------------------------------------------------

African investigators and institutions have maintained a strong presence in the production of CEAs targeted to African countries, with 64% of studies including at least one author with an African affiliation and 51% including more than one. However, less than one‐quarter of *first* authors (23%) reported an African affiliation. At the institution level, the London School of Hygiene & Tropical Medicine, UK, contributed the most studies (*n* = 58), whereas Makerere University, Uganda (*n* = 25), University of Cape Town, South Africa (*n* = 23), and University of the Witwatersrand, South Africa (*n* = 20), were the top three African institutions (Table [2](#hec4029-tbl-0002){ref-type="table"}).

###### 

Institutional capacity

                                                                                                                     Number of studies   \% of total studies (*n* = 358)
  ------------------------------------------------------------------------------------------------------------------ ------------------- ---------------------------------
  Any author                                                                                                                             
  African affiliation                                                                                                228                 64%
  No African affiliation                                                                                             130                 36%
  Multiple African affiliations                                                                                      183                 51%
  First author                                                                                                                           
  African affiliation                                                                                                81                  23%
  No African affiliation                                                                                             277                 77%
  Senior author                                                                                                                          
  African affiliation                                                                                                92                  26%
  No African affiliation                                                                                             266                 74%
  Top 5 worldwide institutions                                                                                                           
  London School of Hygiene & Tropical Medicine                                                                       58                  16%
  World Health Organization                                                                                          42                  12%
  Harvard University                                                                                                 35                  10%
  Johns Hopkins University                                                                                           34                  9%
  U.S. Centers for Disease Control and Prevention                                                                    28                  8%
  Top 5 African institutions                                                                                                             
  Makerere University                                                                                                25                  7%
  University of Cape Town                                                                                            23                  7%
  University of the Witwatersrand                                                                                    20                  6%
  Kenya Medical Research Institute                                                                                   7                   2%
  Tanzania Ministry of Health                                                                                        7                   2%
  Top 5 worldwide authors[^a^](#hec4029-note-0003){ref-type="fn"}                                                                        
  Kahn, James G. (University of California, San Francisco)                                                           15                  4%
  Marseille, Elliot (University of California, San Francisco)                                                        10                  3%
  Baltussen, Rob (Radboud University)                                                                                9                   3%
  Chisholm, Dan (World Health Organization)                                                                          9                   3%
  Hallett, Timothy B. (Imperial College London)                                                                      8                   2%
  Top 5 African‐based authors[^a^](#hec4029-note-0003){ref-type="fn"} ^,^ [^b^](#hec4029-note-0004){ref-type="fn"}                       
  Lamorde, Mohammed (Makerere University)                                                                            8                   2%
  Kuznik, Andreas (Bayero University; Makerere University; Regeneron)                                                7                   2%
  Manabe, Yukari C. (Johns Hopkins University)                                                                       7                   2%
  Cleary, Susan M. (University of Cape Town)                                                                         6                   2%
  Mermin, Jonathan (U.S. Centers for Disease Control and Prevention)                                                 6                   2%
  Top 5 African countries                                                                                                                
  South Africa                                                                                                       53                  15%
  Uganda                                                                                                             47                  13%
  Kenya                                                                                                              32                  9%
  Nigeria                                                                                                            23                  6%
  Tanzania                                                                                                           23                  6%

Rankings based on co‐authorship irrespective of author order.

We relied on the information available in each study to determine each author\'s institution of affiliation and country of affiliation. We considered authors to have an "African‐based affiliation" if the country of affiliation reported for their affiliated institution was a country in Africa. For example, since the U.S. Centers for Disease Control and Prevention have programs and placements in Kenya and Uganda, we consider these to be "African‐based affiliations."

Although researchers from 76 different countries contributed to generating economic evidence for Africa, research collaborations tended to be based in the same country. When African researchers collaborated internationally, they most frequently worked with researchers based in the United States, followed by the United Kingdom ([Appendix S6: Figure A](#hec4029-supitem-0001){ref-type="supplementary-material"}). Within the African region, authors based in Uganda and Nigeria worked together most frequently (*n* = 6), highlighting the presence of regional collaboration within Africa. There was little collaboration between researchers in countries in North Africa and sub‐Saharan Africa ([Appendix S6: Figure B, Appendix S7: Table C](#hec4029-supitem-0001){ref-type="supplementary-material"}).

3.4.. Study characteristics by top African institutions {#hec4029-sec-0010}
-------------------------------------------------------

The characteristics of CEAs produced by top institutions (ranked by number of published CEAs) varied in a number of ways, compared with those by other African institutions ([Appendix S7: Table G](#hec4029-supitem-0001){ref-type="supplementary-material"}). The top three institutions more frequently reported QALYs as a health outcome measure (35% vs. 15%, *p* \< .001) and focused most frequently on HIV/AIDs and tuberculosis (53% vs. 31%, *p* \< .001). They were also more likely to perform advanced analyses, such as probabilistic sensitivity analysis (60% vs. 42%, *p* \< .05), and published CEAs with a higher average quality score, though the difference was not statistically significant (mean quality score: 5.0 vs. 4.8, *p* = .194). Top institutions were also more adherent to the iDSI reference case\'s methodological (65% vs. 57%, *p* \< .001) and reporting guidelines (76% vs. 72%, *p* \< .05) and surpassed the average adherence scores across all cost‐per‐DALY studies evaluated relative to the iDSI reference case (65% vs. 60% for methodological standard; 76% vs. 74%for reporting standard; Table [3](#hec4029-tbl-0003){ref-type="table"}; Emerson et al., [2019](#hec4029-bib-0017){ref-type="ref"}).

###### 

Adherence to the iDSI reference case among CEAs produced by top and other African institutions

  iDSI reference case adherence score principle[^b^](#hec4029-note-0006){ref-type="fn"}   Top African institutions[^a^](#hec4029-note-0005){ref-type="fn"} (number of CEAs: 31)   Other African institutions (number of CEAs: 90)   Difference (95% CI)     *p* value   Full adherence score sample from Emerson et al., [2019](#hec4029-bib-0017){ref-type="ref"} (number of CEAs: 398)
  --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------- ----------- ------------------------------------------------------------------------------------------------------------------
  Reporting                                                                                                                                                                                                                                                             
  Overall                                                                                 76.34 (1.22)                                                                            72.38 (.93)                                       3.96 (.51, 7.41)        .0247       73.9
  Budget impact                                                                           9.68 (5.40)                                                                             4.44 (2.18)                                       5.23 (−4.43, 14.89)     .286        9.3
  Comparator                                                                              98.39 (1.61)                                                                            94.44 (1.67)                                      3.94 (−1.99, 9.88)      .191        96.86
  Costs                                                                                   51.61 (1.61)                                                                            52.22 (1.35)                                      −0.61 (−5.53, 4.32)     .807        53.52
  Equity                                                                                  9.68 (5.40)                                                                             3.33 (1.90)                                       6.34 (−2.61, 15.30)     .163        6.53
  Evidence                                                                                96.77 (3.23)                                                                            96.67 (1.90)                                      0.11 (−7.33, 7.54)      .977        95.23
  Heterogeneity                                                                           38.71 (8.89)                                                                            43.33 (5.25)                                      −4.62 (−25.14, 15.89)   .656        37.19
  Outcome                                                                                 45.16 (9.09)                                                                            50 (5.30)                                         −4.84 (−25.60, 15.93)   .645        53.52
  Perspective                                                                             96.77 (3.23)                                                                            81.11 (4.15)                                      15.66 (1.14, 30.18)     .0347       85.43
  Time horizon                                                                            90.32 (3.61)                                                                            78.89 (3.53)                                      11.43 (−1.22, 24.08)    .076        81.91
  Transparency                                                                            89.86 (1.90)                                                                            84.76 (1.62)                                      5.10 (−.82, 11.02)      .09         86.32
  Uncertainty                                                                             100                                                                                     100                                               ‐                       ‐           100
  Methods                                                                                                                                                                                                                                                               
  Overall                                                                                 65.37 (1.87)                                                                            56.73 (1.27)                                      8.64 (3.84, 13.44)      .0005       59.63
  Budget impact                                                                           6.45 (4.49)                                                                             5.56 (2.43)                                       0.90 (−8.81, 10.6)      .855        10.05
  Comparator                                                                              51.61 (9.12)                                                                            32.22 (4.95)                                      19.39 (−.40, 39.18)     .055        35.68
  Costs                                                                                   72.58 (5.60)                                                                            70.56 (3.52)                                      2.03 (−11.53, 15.58)    .768        65.33
  Equity                                                                                  9.68 (5.40)                                                                             3.33 (1.90)                                       6.34 (−2.61, 15.30)     .163        6.53
  Evidence                                                                                74.19 (7.99)                                                                            62.22 (5.14)                                      11.97 (−7.70,31.65)     .231        43.12
  Heterogeneity                                                                           38.71 (8.89)                                                                            43.33 (5.25)                                      −4.62 (−25.4, 15.89)    .656        37.19
  Outcome                                                                                 100                                                                                     100                                               ‐                       ‐           100
  Perspective                                                                             61.29 (4.47)                                                                            58.89 (2.57)                                      2.40 (−7.70, 12.50)     .639        63.82
  Time horizon                                                                            69.89 (4.97)                                                                            47.78 (3.61)                                      22.11 (8.61, 35.62)     .0015       57.2
  Transparency                                                                            95.70 (2.04)                                                                            86.67 (1.96)                                      9.03 (2.01, 16.06)      .012        89.45
  Uncertainty                                                                             65.30 (4.50)                                                                            56.30 (2.82)                                      9.30 (−1.56, 20.15)     .093        57.04

We consider CEAs co‐authored by the top three African institutions (those contributing to more than 10 studies) "Top African Institution Studies," whereas all other studies co‐authored by other African institutions are considered "Other African Institution Studies."

This analysis includes only studies that included methods and reporting reference case adherence scores generated by Emerson et al. ([2019](#hec4029-bib-0017){ref-type="ref"}). Scores are based on "required" methodological specifications (*n* = 19) and reporting standards (*n* = 21). Raw scores are converted to a percentage of total possible points, measured as normalized adherence score (0% = no adherence, i.e., no requirements adhered to; 100% = full adherence, all requirements adhered to). We provide the methodological summary in [Appendix S4](#hec4029-supitem-0001){ref-type="supplementary-material"}.

4.. DISCUSSION {#hec4029-sec-0011}
==============

Economic evidence for assessing the value of health interventions in Africa has grown substantially over the past decade and is available for every African country across various disease areas. Though it can be challenging to understand the value offered by potentially outdated studies, the vast majority included have been published since 2008 (85%).This progress highlights the potential to inform prioritization decisions for designing UHC packages. Our study, however, finds that the volume of available evidence varies markedly by country.

Compared with economic evaluations conducted for other regions (Butt et al., [2019](#hec4029-bib-0006){ref-type="ref"}; Neumann et al., [2018](#hec4029-bib-0030){ref-type="ref"}; Pitt et al., [2016](#hec4029-bib-0036){ref-type="ref"}), African studies remain more focused on interventions for communicable diseases (77% of published CEAs); Global Burden of Disease Collaborative Network, [2018](#hec4029-bib-0021){ref-type="ref"}). The focus of funders and international organizations might also contribute to a disproportionately large number of economic evaluations in communicable diseases, relative to the disease burden (GAVI: The Vaccine Alliance, [2019](#hec4029-bib-0020){ref-type="ref"}). With the growing burden of non‐communicable diseases (NCD) (Global Burden of Disease Collaborative Network, [2018](#hec4029-bib-0021){ref-type="ref"}), more attention from ministries of health, funders, and international organizations is needed to generate economic evidence for interventions targeting NCDs.

The capacity for generating such evidence within most African institutions remains somewhat limited, highlighting the need to invest in capacity‐building activities while continuing to leverage existing international collaborations. A good model of such collaboration is the long‐standing partnership between the Kenya Medical Research Institute and the Wellcome Trust to improve health across the region and develop African scientific leaders ([2019](#hec4029-bib-0027){ref-type="ref"}).

The top African institutions have produced economic evidence with better methodological quality and advanced analysis. Building capacity around these institutions (e.g., the development of regional hubs) would be valuable to generate more transferable economic evidence across African countries, considering epidemiologic and economic similarities in the region. Also, in the absence of local guidelines, funders may request economic evaluations to follow the practice guidelines when commissioning economic evaluations to ensure quality and comparability of studies.

Our findings show the widespread collaboration among international researchers, yet collaboration patterns are not equivalent across the African regions. This pattern perhaps reflects broader systemic differences between the regions, such as donor funding, political environments, and existing partnerships between academics and the local government. Encouraging knowledge transfer among African institutions---through establishing HTA network in Africa, such as HTAsiaLink ([2019](#hec4029-bib-0025){ref-type="ref"}), and using the African Health Economics and Policy Association (AfHEA; [2019](#hec4029-bib-0001){ref-type="ref"}) as a platform---could be an essential next step to develop technical collaboration.

Our study has some limitations. First, we only included published cost‐per‐QALY or cost‐per‐DALY studies, excluding other types of economic analyses (e.g., benefit--cost analyses or cost‐per‐natural‐unit studies). A previous study suggested that cost‐utility analyses accounted for at least half of economic evaluations, whereas the majority of other studies are other types of CEAs (Pitt et al., [2016](#hec4029-bib-0036){ref-type="ref"}). In the context of resource prioritization, however, studies reporting outcomes in QALYs or DALYs are essential so that interventions for different disease areas can be comparable and informative for designing UHC. Also, we did not capture the non‐English language and non‐published economic analyses, such as government documents or the gray literature. Considering that all economic evaluations addressing LMICs were published in English (Pitt et al., [2016](#hec4029-bib-0036){ref-type="ref"}) and that only one HTA agency has been formalized in Africa (i.e., Tunisia; Egypt also incorporates some elements of HTA) (INEAS, 2020; Elsisi et al., [2013](#hec4029-bib-0016){ref-type="ref"}; El‐Sisi & Eldessouki, [2018](#hec4029-bib-0015){ref-type="ref"}), the number of potentially excluded studies is likely to be minimal. Finally, despite its use in the past (Butt et al., [2019](#hec4029-bib-0006){ref-type="ref"}; Neumann et al., [2016](#hec4029-bib-0033){ref-type="ref"}; Neumann, Fang, & Cohen, [2009](#hec4029-bib-0031){ref-type="ref"}; Neumann, Stone, Chapman, Sandberg, & Bell, [2000](#hec4029-bib-0032){ref-type="ref"}), the quality rating used in this study is a subjective measure that may not fully capture the appropriateness of input estimates. An alternative approach is to measure each article\'s adherence to reporting and methodological guidelines (Emerson et al., [2019](#hec4029-bib-0017){ref-type="ref"}).

5.. CONCLUSION {#hec4029-sec-0012}
==============

While there has been a rapid growth of economic evidence for African countries, this review highlights a need for more information to help inform UHC development efforts and address changing disease burden patterns. Increasing the capacity of regional institutions to produce high‐quality economic evidence and facilitating knowledge transfer among African institutes has the potential to generate more transferable economic evidence and promote better decision‐making by providing policymakers with more high‐quality, contextually relevant information.
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